Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Prostate Cancer: early-phase trial registry
22 of 42 indexed Metastatic Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #347 of 28,707 conditions by registered trial count.
42 US clinical trials · 22 currently recruiting · #347 of 28,707 conditions by registered trial count
Metastatic Prostate Cancer: 42 US clinical trials tracked, 22 recruiting.
Metastatic Prostate Cancer is the subject of 42 registered US clinical trials on ClinicalTrials.gov, 22 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition metastatic-prostate-cancer
OPEN 22 | RECR 52% | LATE 6 | EARLY 28 | RANK #347 | SPON 4
Volume-matched condition peers
Nearest open-share peer: End-Stage Kidney Disease (52% recruiting · 21 trials)
Metastatic Prostate Cancer lists 22 open slots (52% of 42 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Prostate Cancer is recruiting above its size-band peers.
22 of 42 indexed trials (52.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 4 of 42 trials (9.5%). 28 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Prostate Cancer enrolment sits around 71 participants.
Median target enrolment is 71 among the 42 trials that report a genuine target (sentinel values excluded). 25 of those (59.5%) plan for fewer than 100 participants.
-
Metastatic Prostate Cancer research is mostly interventional.
40 interventional and 2 observational studies make up this index (95.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
42 total, page 1 of 1
Collection of Blood From Patients With Prostate Cancer
National Cancer Institute (NCI)
NCT00923221
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
VA Office of Research and Development
NCT04787744
Physician- and Patient-based Barriers to NGS Testing
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07209176
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ORIC Pharmaceuticals
NCT05413421
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Genentech
NCT05800665
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
University of Utah
NCT06112990
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
AstraZeneca
NCT07181161
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
Dana-Farber Cancer Institute
NCT06040125
Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer
University of Utah
NCT07032584
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
ImmunoGenesis
NCT06782555
Study of AZD0754 in Participants With Metastatic Prostate Cancer
AstraZeneca
NCT06267729
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06616597
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
VA Office of Research and Development
NCT05011383
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
Case Comprehensive Cancer Center
NCT06738303
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Dana-Farber Cancer Institute
NCT06303713
A Study of Tarlatamab for People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT07111507
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Brigham and Women's Hospital
NCT06062745
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
NCT07145177
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05751941
Remotely Monitored Exercise Interventions in Patients with MCSPC Undergoing ADT (Prostate 006)
Paul Viscuse
NCT06429813
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
NCT06706921
7-Days Water-Only Fasting Trial in Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06826924
INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)
Movember Foundation
NCT02730338
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
OncoC4
NCT04140526
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Exelixis
NCT04446117
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
Janssen Research & Development
NCT04662580
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
AstraZeneca
NCT05367440
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
NCT04478279
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
Alliance Foundation Trials
NCT04335682
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT03173924
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT04030338
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
Andrew J. Armstrong, MD
NCT04709276
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Dana-Farber Cancer Institute
NCT04846478
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT04262154
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
Brigham and Women's Hospital
NCT06479187
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Columbia University
NCT03585114
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Praful Ravi, MB BCHir, MRCP
NCT05617885
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Hoffmann-La Roche
NCT03072238
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
Progenics Pharmaceuticals
NCT03939689
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics
NCT04887506
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT02278055
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
University of California, San Francisco
NCT03248570
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 14 |
| Phase 3 | 4 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Prostate Cancer page
42 registered trials, 22 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 22 Metastatic Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Metastatic Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Prostate Cancer condition card totals 42 registered trials; most-linked intervention Enzalutamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.